Pfizer's Obesity Drug Candidate Shows Promising 12.3% Weight Loss in Mid-Stage Trial
Pfizer has announced positive Phase 2b results for its injectable obesity treatment, reporting significant weight reduction and a favorable safety profile as it gears up for a broad late-stage clinical program.